Directori de persones
Serafin Morales Murillo

Serafin Morales Murillo

Grau: Doctor/a

973 70 53 03
smorales.lleida.ics(ELIMINAR)@gencat.cat

ResearcherID: http://www.researcherid.com/rid/L-7216-2019

Publicacions

  • Pont, M; Marques, M; Sorolla, MA; Parisi, E; Urdanibia, I; Morales, S; Salud, A; Sorolla, A

    Applications of CRISPR Technology to Breast Cancer and Triple Negative Breast Cancer Research

    Cancers 15 -. .

    [doi:10.3390/cancers15174364]

  • Schmid P; Cortes J; Joaquim A; Jañez NM; Morales S; Díaz-Redondo T; Blau S; Neven P; Lemieux J; García-Sáenz JÁ; Hart L; Biyukov T; Baktash N; Massey D; Burris HA 3rd; Rugo HS

    XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.

    BREAST CANCER RESEARCH 25 67-67. .

    [doi:10.1186/s13058-023-01649-w]

  • Martín M; Zielinski C; Ruiz-Borrego M; Carrasco E; Ciruelos EM; Muñoz M; Bermejo B; Margelí M; Csöszi T; Antón A; Turner N; Casas MI; Morales S; Alba E; Calvo L; de la Haba-Rodríguez J; Ramos M; Murillo L; Santaballa A; Alonso-Romero JL; Sánchez-Rovira P; Corsaro M; Huang X; Thallinger C; Kahan Z; Gil-Gil M

    Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.

    EUROPEAN JOURNAL OF CANCER 168 12-24. .

    [doi:10.1016/j.ejca.2022.03.006]

  • Marques, M; Sorolla, MA; Urdanibia, I; Parisi, E; Hidalgo, I; Morales, S; Salud, A; Sorolla, A

    Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?

    Cancers 14 -. .

    [doi:10.3390/cancers14051101]

  • Ocaña A; Chacon, JI; Calvo, L; Anton, A; Mansutti, M; Albanell, J; Martinez, MT; Lahuerta, A; Bisagni, G; Bermejo, B; Semiglazov, V; Thill, M; Chan, ARE; Morales, S; Herranz, J; Tusquets, I; Chiesa, M; Caballero, R; Valagussa, P; Bianchini, G; Alba, E; Gianni, L

    Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.

    Frontiers in oncology 11 827625-827625. .

    [doi:10.3389/fonc.2021.827625]

  • Yao, HM; Jones, SR; Morales, S; Moosavi, S; Zhang, J; Freyman, A; Ottery, FD

    Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer

    CANCER CHEMOTHERAPY AND PHARMACOLOGY 88 1033-1048. .

    [doi:10.1007/s00280-021-04355-6]

  • Kahan, Z; Gil-Gil, M; Ruiz-Borrego, M; Carrasco, E; Ciruelos, E; Munoz, M; Bermejo, B; Margeli, M; Anton, A; Casas, M; Csoszi, T; Murillo, L; Morales, S; Calvo, L; Lang, I; Alba, E; de la Haba-Rodriguez, J; Ramos, M; Lopez, IA; Gal-Yam, E; Garcia-Palomo, A; Alvarez, E; Gonzalez-Santiago, S; Rodriguez, CA; Servitja, S; Corsaro, M; Rodrigalvarez, G; Zielinski, C; Martin, M

    Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    EUROPEAN JOURNAL OF CANCER 156 70-82. .

    [doi:10.1016/j.ejca.2021.07.004]

  • Gil-Gil, MJ; Bellet, M; Bergamino, M; Morales, S; Barnadas, A; Manso, L; Saura, C; Fernandez-Ortega, A; Garcia-Martinez, E; Martinez-Janez, N; Mele, M; Villagrasa, P; Celiz, P; Martin, XP; Ciruelos, E; Pernas, S

    Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study

    Frontiers in oncology 11 -. .

    [doi:10.3389/fonc.2021.645026]

  • Martin, M; Zielinski, C; Ruiz-Borrego, M; Carrasco, E; Turner, N; Ciruelos, EM; Munoz, M; Bermejo, B; Margeli, M; Anton, A; Kahan, Z; Csoszi, T; Casas, MI; Murillo, L; Morales, S; Alba, E; Gal-Yam, E; Guerrero-Zotano, A; Calvo, L; de la Haba-Rodriguez, J; Ramos, M; Alvarez, I; Garcia-Palomo, A; Bartlett, CH; Koehler, M; Caballero, R; Corsaro, M; Huang, X; Garcia-Saenz, JA; Chacon, JI; Swift, C; Thallinger, C; Gil-Gil, M

    Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL

    ANNALS OF ONCOLOGY 32 488-499. .

    [doi:10.1016/j.annonc.2020.12.013]

  • Griguolo, G; Serna, G; Pascual, T; Fasani, R; Guardia, X; Chic, N; Pare, L; Pernas, S; Munoz, M; Oliveira, M; Vidal, M; Llombart-Cussac, A; Cortes, J; Galvan, P; Bermejo, B; Martinez, N; Lopez, R; Morales, S; Garau, I; Manso, L; Alarcon, J; Martinez, E; Villagrasa, P; Prat, A; Nuciforo, P

    Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

    npj Precision Oncology 5 -. .

    [doi:10.1038/s41698-021-00163-6]

  • Morales Murillo, Serafin; Gasol Cudos, Ariadna; Veas Rodriguez, Joel; Canosa Morales, Carles; Melé Olivé, Jordi; Vilardell Villellas, Felip; Sanchez Guzman, Douglas Rene; Iglesias Martínez, Edelmiro; Salud Salvia, Antonieta

    Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer

    BREAST 56 35-41. .

    [doi:10.1016/j.breast.2021.01.001]

  • Chan A; Moy B; Mansi J; Ejlertsen B; Holmes FA; Chia S; Iwata H; Gnant M; Loibl S; Barrios CH; Somali I; Smichkoska S; Martinez N; Alonso MG; Link JS; Mayer IA; Cold S; Murillo SM; Senecal F; Inoue K; Ruiz-Borrego M; Hui R; Denduluri N; Patt D; Rugo HS; Johnston SRD; Bryce R; Zhang B; Xu F; Wong A; Martin M; ExteNET Study Group

    Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.

    CLINICAL BREAST CANCER 21 80-. .

    [doi:10.1016/j.clbc.2020.09.014]

Projectes

  • Development of Computer Application (Apps) for Information and Monitoring of Patients with Breast Cancer at the Hospital Arnau de Vilanova De Lleida
  • SELECCIÓN DE TRATAMIENTO CON QUIMIOTERAPIA NEOADYUVANTE EN PACIENTES CON CÁNCER DE MAMA EN ESTADIO PRECOZ Y CON RECEPTORES HORMONALES POSITIVOS MEDIANTE LA DETERMINACIÓN DE LA PLATAFORMA ONCOTYPE, CF DNA EN SANGRE PERIFÉRICA Y CAMBIOS DEL MARCADOR KI67 EN TEJIDO TUMORAL.
  • Cáncer de mama: utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0 cm) tras quimioterapia neoadyuvante